This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Harbor BioSciences, Inc.
Drug Names(s): HE2000, 16a-bromoepiandrosterone hemihydrate
Description: HE2000 is an immune regulating hormone (IRH) that may regulate the immune system back towards homeostasis when used in the treatment of a variety of disease conditions.
Deal Structure: In January 2011, Harbor BioSciences announced that it has licensed the research and development and commercialization rights for three of its products (Triolex/HE3286, Apoptone/HE3235, and HE2000) exclusively in the Peoples Republic of China and Hong Kong, to the China State Institute of Pharmaceutical Industry (CIPI). Harbor BioSciences retains the rights to these products in the U.S. and the rest of the world, and CIPI will make available to the company all pre-clinical and clinical data it generates.
Harbor BioSciences will receive milestone payments for Triolex, Apoptone and HE2000, excluding infectious diseases, at the completion of Phase II and III clinical studies and upon approval by the SFDA. Harbor BioSciences will also receive royalties based on net profits for the life of each agreement. In addition, Harbor BioSciences is CIPIs sole agent with commercial development and sales rights to all of CIPIs improvements that are sold outside the licensed territory. Sales of...See full deal structure in Biomedtracker
Partners: China State Institute of Pharmaceutical Industry (CSIPI)
Additional information available to subscribers only: